CompanyLGND LGNDZ LGNXZ LGNYZ LGNZZNasdaq, OTCSan Diego, CA

Ligand Pharmaceuticals Inc

Ligand finances late-stage clinical development programs for biopharmaceutical companies in exchange for royalty interests.

SEC EDGAR ClinicalTrials.gov ligand.com

424B5Sep 25Latest SEC filing

Sep 24Latest story

September 2026

Ligand agrees to fund AvenCell's CAR-T pipeline for up to $47 million

Sep 24FinancingLigand Pharmaceuticals Inc

Ligand pays $23 million for royalty rights on Santen's myopia drug Ryjunea

Sep 22Regulatory decisionLigand Pharmaceuticals Inc

August 2026

Ligand raises EPS guidance floor, closes XOMA Royalty deal, reports pipeline progress

Aug 6Quarterly updateLigand Pharmaceuticals Inc

July 2026

Ligand closes $739 million acquisition of XOMA Royalty

Jul 14M&ALigand Pharmaceuticals Inc